(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 October 2020 (08.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/206098 A9

(51) International Patent Classification:
A61K 48/00 (2006.01) *C12N 15/864* (2006.01)

(21) International Application Number:
PCT/US2020/026356

(22) International Filing Date:
02 April 2020 (02.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/828,949	03 April 2019 (03.04.2019)	US
62/856,533	03 June 2019 (03.06.2019)	US
62/946,158	10 December 2019 (10.12.2019)	US

(71) Applicant: **REGENXBIO INC.** [US/US]; 9600 Blackwell Road, Suite 210, Rockville, MD 20850 (US).

(72) Inventors: **DANOS, Olivier**; 1349 Lexington Avenue, Apt. 4G, New York, NY 10128 (US). **VAN EVEREN, Sherri**; 823 Paulson Circle, Menlo Park, CA 94025 (US). **YOO, Jesse, I.**; 1124 Austin Avenue NE, Atlanta, GA 30307 (US). **PATEL, Samir, Maganbhai**; 1315 Clifton Street, Apt. 519, Washington, DC 20009 (US). **GHANEKAR, Avanti, Arvind**; 4424 Laclede Avenue, St. Louis, MO 63018 (US). **O'BERRY, Anthony, Ray**; 2251 Regina Drive, Clarksburg, MD 20871 (US). **IRWIN-PACK, Kim, Rees**; 3481 S. Monte Verde Drive, Millcreek, UT 84109 (US). **CURTISS, Darin, Thomas**; 11813 Wood Thrush Lane, Potomac, MD 20854 (US).

(74) Agent: **MARTINEK, Sebastian** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: GENE THERAPY FOR EYE PATHOLOGIES




FIG. 1

(57) Abstract: Compositions and methods are described for the delivery of therapeutic products (such as therapeutic proteins (for example, antibodies), therapeutic RNAs (for example, shRNAs, siRNAs, and miRNAs), and therapeutic aptamers) to the retina/vitreal humour in the eyes of human subjects to treat pathologies of the eye, involving, for example, recombinant viral vectors such as recombinant adeno-associated virus (rAAV) vectors.

WO 2020/206098 A9

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) **Date of publication of this corrected version:**
04 February 2021 (04.02.2021)

(15) **Information about Correction:**
see Notice of 04 February 2021 (04.02.2021)